Workstream Type: Policy Comments

Formal responses to government RFIs

  • Incentives for Rare Diseases: the Right Healthcare Priorities?

  • Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019

  • Dr. Bach Testifies at U.S. Senate Committee on Finance’s First Hearing of Session

    Dr. Bach Testifies at U.S. Senate Committee on Finance’s First Hearing of Session

  • Competitive Acquisition Program

  • TEDMED Talk: Changing the Drug Pricing Game with Dr. Peter Bach

  • DPL Responds to CMS Proposed Changes to OPPS Policy

  • DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)

  • DPL responds to HHS Blueprint (May 16, 2018)

  • The Price Tag on Progress — Chemotherapy for Colorectal Cancer